DLH will serve as the Operations and Data Coordinating Center for the B Cell Depletion in Multiple Sclerosis (BcDMS) Registry. BcDMS is a project of the Consortium of Multiple Sclerosis Centers (CMSC), a long time DLH partner.
B cell depletion uses monoclonal antibodies to attack the B cells that cross from MS patients’ blood to their brain or spinal cord. In recent years, this therapy has become a mainstay of treatment for relapsing forms of multiple sclerosis (MS), but the long-term safety of the practice remains largely unknown.
DLH will provide administrative, operational, information technology, data management and statistical support to a longitudinal registry of participants on B cell depleting therapies. Our team will establish and manage the project infrastructure; develop and implement the study protocol and the registry database; onboard sites to enroll participants into the registry; provide interim and final analyses; and prepare a final manuscript.
“We are excited for this opportunity to expand our support for research on multiple sclerosis,” said Jeanine Christian, President of DLH’s Public Health & Scientific Research (PHSR) operating unit. “From developing and studying successful models of care, to sharing key insights and knowledge among researchers and all those affected by MS, CMSC is leading the way in improving the lives of those affected by this disease.”
For more information on the Consortium of Multiple Sclerosis Centers (CMSC), please visit the organization’s website.